Clinical trials: pills and oral medicines
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Suicidal Ideation
Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Female suicide attempts occur more often in the weeks before and after menses onset, and have been linked to ovarian hormone withdrawal.
- Trial name
- CLEAR-3 (NCT04112368)
- Testing
- Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Illinois Chicago
Non-alcoholic Fatty Liver Disease in Women With PCOS
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
- Trial name
- NCT03617263
- Testing
- Saroglitazar Magnesium 4 mg Tablet
- Where
- 19 sites in United States, Mexico
- Volunteers
- 60 people
- Sponsor
- Zydus Therapeutics Inc.
Schizophrenia
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely…
- Trial name
- UNITE-001 (NCT05919823)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 28 sites in China
- Volunteers
- 202 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Type 1 Diabetes Mellitus
Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes
This is a prospective, randomized trial to evaluate the effectiveness of using educational modules accessed through a bedside tablet in patients newly diagnosed with Type 1 Diabetes as an adjunct to *standard Children's Hospital…
- Trial name
- NCT03534193
- Testing
- Molly Center Diabetes Care Guide (Paper-based), Tablet based interactive diabetes education modules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Hackensack Meridian Health
Hydrocortisone, Depression
Exploring the Effects of Corticosteroids on the Human Hippocampus
Chronic corticosteroid (CS) exposure is associated with changes in memory and the hippocampus in both humans and in animal models.
- Conditions
- Hydrocortisone, Depression, Healthy Volunteers
- Trial name
- NCT03896659
- Testing
- Hydrocortisone Oral
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson Disease, Idiopathic Parkinson Disease
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Parkinson's disease (PD) is a neurodegenerative disorder of unknown cause that affects more than a million Americans. It's most prominent pathology is the degeneration of dopaminergic neurons in the brain.
- Trial name
- NCT02445651
- Testing
- Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Thomas Jefferson University
Infusion Reaction, Monoclonal Antibody
Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
The use of monoclonal antibodies (MA) either alone or as part of chemoimmunotherapy in oncology, benign and malignant hematology is expanding.
- Trial name
- NCT04198623
- Testing
- Montelukast 10 Mg Oral Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Depression, Bipolar, Depression, Unipolar
Pramipexole to Target "Anhedonic Depression"
The heterogeneity of depression suggests that different neurocircuits and pathophysiological mechanisms are involved. Anhedonia - the inability to experience pleasure from, or the lack of motivation to carry out, usually…
- Conditions
- Depression, Bipolar, Depression, Unipolar, Dysthymia, Anhedonia
- Trial name
- PILOT-PRAXOL (NCT04121091)
- Testing
- Pramipexole Pill
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Region Skane
Asthma, Obesity
MitoQ for the Treatment of Metabolic Dysfunction in Asthma
A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo.
- Trial name
- MIMDA (NCT04026711)
- Testing
- Mitoquinol
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Vermont
Gastro Intestinal Stromal Tumor
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Gastro intestinal stromal tumors (GIST) are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT or the PDGFR alpha protein1.
- Trial name
- METAGIST (NCT03963544)
- Testing
- oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
- Where
- France
- Volunteers
- 492 people
- Sponsor
- Institut Bergonié
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines.
- Trial name
- PIONEER PLUS (NCT04707469)
- Testing
- Oral semaglutide
- Where
- 228 sites in United States, Australia and 13 more
- Volunteers
- 1,606 people
- Sponsor
- Novo Nordisk A/S
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Adult Solid Tumor
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in…
- Trial name
- NCT05147272
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 67 people
- Sponsor
- Debiopharm International SA
Autoimmune Diseases, Systemic Inflammatory Process
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish…
- Conditions
- Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis
- Trial name
- VITAL (NCT01351805)
- Testing
- Fish Oil, Vitamin D
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Sarcoidosis
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis.
- Trial name
- GRADS (NCT02134717)
- Testing
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kevin F. Gibson
Pain, Postoperative
Postoperative Pain Management in Rhinoplasty
The primary purpose of the study is to determine adequacy of postoperative pain control after nasal surgery in patients prescribed Acetaminophen (325mg) + Hydrocodone (5mg) compared to Acetaminophen(325mg) + Ibuprofen (200mg)for…
- Trial name
- NCT03584152
- Testing
- Norco 5Mg-325Mg Tablet, Tylenol 325Mg Caplet, Ibuprofen 200 mg
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Stanford University
Gout, Hyperuricemia
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a…
- Trial name
- NCT03934099
- Testing
- LC350189 formulated capsule
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- LG Chem
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.